The two subgroups did not differ regarding patient gender distribution, age, histology, presence of chronic thyroiditis, RAI indication (remnant ablation, adjuvant treatment, or known structural disease), RAI dose, the percentage of patients receiving RAI for the first time, and the levels of Tg, Anti-Tg and ACTH. The gene discussed is POMC; the disease is Hashimoto thyroiditis.